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ABSTRACT: The L55P transthyretin (TTR) familial amyloid polyneuropathy-associated variant is distinct
from the other TTR variants studied to date and the wild-type protein in that the L55P tetramer can
dissociate to the monomeric amyloidogenic intermediate and form fibril precursors under physiological
conditions (pH 7.0, 37 °C). The activation barrier associated with L55P-TTR tetramer dissociation is
lower than the barrier for wild-type transthyretin dissociation, which does not form fibrils under
physiological conditions. The L55P-TTR tetramer is also very sensitive to acidic conditions, readily
dissociating to form the monomeric amyloidogenic intermediate between pH 5.5-5.0 where the wild-
type TTR adopts a nonamyloidogenic tetrameric structure. The formation of the L55P monomeric
amyloidogenic intermediate involves subtle tertiary structural changes within the â-sheet rich subunit as
discerned from Trp fluorescence, circular dichroism analysis, and ANS binding studies. The assembly of
the L55P-TTR amyloidogenic intermediate at physiological pH (pH 7.5) affords protofilaments that elongate
with time. TEM studies suggest that the entropic barrier associated with filament assembly (amyloid
fibril formation) is high in vitro, amyloid being defined by the laterally assembled four filament structure
observed by Blake upon isolation of “fibrils” from the eye of a FAP patient. The L55P-TTR protofilaments
formed in vitro bind Congo red and thioflavin T (albeit more weakly than the fibrils produced at acidic
pH), suggesting that the structure observed probably represents an amyloid precursor. The structural
continuum from misfolded monomer through protofilaments, filaments, and ultimately fibrils must be
considered as a possible source of pathology associated with these diseases.
There are several human neurodegenerative diseases
putatively caused by extracellular protein deposition (1). The
most familiar of these include the amyloid diseases, e.g.
Alzheimer’s disease and senile systemic amyloidosis (2-
7). In all amyloid diseases, proteins undergo conformational
changes either before or coincident with their self-assembly
into highly ordered amyloid fibrils. Amyloid fibrils having
a cross â-sheet quaternary structure are typically deposited
in the brain and/or in peripheral tissues and have been linked
to neurodegeneration and/or organ dysfunction by genetic
evidence (2, 8-11). The amyloid hypothesis implicates
amyloid fibrils as the causative agent in amyloid diseases
through a gain of function phenotype. (1, 7, 9, 12-14).
Recent results from several laboratories, including our own,
demonstrate the existence of preamyloid quaternary structural
intermediates (protofilaments), implying that the whole
process of amyloid fibril formation must be considered as a
possible cause of pathology, including the first step in the
process, which is protein misfolding in the case of structurally
well-defined amyloid proteins (14-21).
Understanding the mechanism of how a folded protein is
converted into an insoluble amyloid fibril is critical for
developing inhibition strategies against amyloid formation
(1, 6, 21-25). Small molecule inhibitors may prevent
amyloid disease and, at the very least, provide a means to
critically test the amyloid hypothesis, particularly if they
inhibit the misfolding process (23-26). There are currently
17 amyloidogenic proteins that self-assemble and appear to
cause amyloid disease (1). These proteins do not appear to
be functionally related. A comparison of these proteins, based
on sequence or tertiary structure, reveals a lack of clear
homology. Nevertheless, these amyloidogenic proteins are
capable of forming highly ordered amyloid fibrils of similar
structure in vivo as discerned from X-ray fibril diffraction,
electron and atomic force microscopy morphology, and the
ability to bind amyloid selective dyes, such as Congo red
and thioflavin T (27, 28). The ability of structurally and
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functionally diverse amyloidogenic proteins to form amyloid
fibrils having a common structure can be explained if these
proteins adopt an alternative â-sheet rich fold as a result of
partial denaturation, in the case of folded proteins or linked
self-assembly and conformational changes in the case of
unfolded peptides such as Aâ. The altered conformation
allows a subset of human proteins to self-assemble into a
cross-â amyloid structure, perhaps through common struc-
tural intermediates (1, 6, 16, 21, 29-32).
Transthyretin (TTR) is one of several structurally well-
defined amyloidogenic proteins (including lysozyme and
immunoglobulin light chain) that undergoes a conformational
change and self-associates into amyloid fibrils as a result of
a partial denaturing environment, a destabilizing mutation,
or both (1, 33-37). Extensive structural and genetic infor-
mation on transthyretin make it an ideal amyloid protein to
probe the biochemical mechanism of fibril formation and to
understand the basis for pathology (1, 2, 29, 30, 33, 38-
40), especially when considering that it is not necessary to
cross the blood brain barrier to inhibit TTR fibril formation
with a small molecule. The process of amyloid fibril
formation is implicated as the causative agent in two types
of TTR-associated amyloid diseases, familial amyloid poly-
neuropathy (FAP), which affects approximately 1 in 100,000
persons, and senile systemic amyloidosis (SSA), which
affects, to some extent, 25% of the population over 80 years
of age. The amyloid fibrils of SSA patients are composed
exclusively of wild-type transthyretin (WT-TTR) (4, 41). In
contrast, one of more than seventy single-site variants of TTR
is the predominant component of the FAP fibrils (typically
>90%) (2, 42, 43). Familial amyloid polyneuropathy refers
to an early onset disease where the pathology ranges from
peripheral neuropathy to organ dysfunction (2, 8, 42, 44-
46). While the presence of an amyloidogenic mutation does
not always lead to FAP, all of the early-onset FAP cases are
associated with a TTR mutation, suggesting that the mutation
is necessary but not sufficient for disease onset (2, 40). The
structures of approximately ten FAP-associated variants have
been solved by X-ray crystallography, revealing folds that
are nearly identical with WT- TTR (47).
Extensive data support the hypothesis that single-site FAP-
associated mutations function by destabilizing the native
protein fold, favoring dissociation and the formation of an
alternatively folded monomeric amyloidogenic intermediate
under conditions where the wild-type tetramer is stable. The
formation of the amyloidogenic intermediate allows self-
assembly and, ultimately, amyloid fibril formation (1, 6, 16,
21, 29, 30, 48). A strong correlation exists between the
instability of the FAP variants in vitro (pH or chaotrope-
induced) and the age of FAP onset in vivo, with the least
stable variant (L55P-TTR) having the earliest onset and being
the most pathogenic (onset during the second decade, death
by 38 years of age) (16, 29, 30).
The L55P mutation is in the D-â-strand on the outer edge
of the TTR tetramer, Figure 1. Introduction of Pro into this
strand should disrupt its structure as verified by the recent
X-ray crystal structure; however, this disruption is localized
and does not prevent tetramer formation (49). Previous
studies suggest that the C-strand-loop-D-strand region of
TTR becomes a disordered loop upon formation of the
amyloidogenic intermediate (1, 6, 16, 21, 50-52). It is
known that multiple mutations and deletions in the D-strand
(residues 53-55) result in significant destabilization of the
TTR fold and enhanced amyloid fibril formation under
physiological conditions, corroborating the involvement of
this region in the formation of the TTR amyloidogenic
intermediate (53). The L55P-TTR crystallography results
seem to confirm the structural basis for the extreme amy-
loidogenicity, in that L55P-TTR is already partially biased
toward the putative C-strand-loop-D-strand rearranged struc-
ture, characteristic of the amyloidogenic intermediate (49).
Unlike WT-TTR, the L55P variant can be converted into
protofilaments via partial thermal denaturation (37 °C) under
physiological conditions (vide infra) (16). Sedimentation
velocity experiments, reveal that the L55P-TTR tetramer
slowly dissociates to a monomer (pH 7.0, 37 °C) prior to
protofilament formation. Prior to this discovery, little atten-
tion was paid to the amyloidogenic potential of L55P-TTR
under physiological conditions, hence the presence of soluble
amyloid protofilaments went undetected in solutions that
were thought to be homogeneous (tetrameric). These oligo-
meric intermediates in older samples complicate the inter-
pretation of biophysical measurements.
Motivated by the fact that L55P-TTR has not been well-
characterized in solution, we sought to understand the basis
for its extreme amyloidogenicity. Fluorescence and circular
dichroism spectroscopy were used to monitor tertiary struc-
FIGURE 1: Ribbon diagram of the wild-type TTR monomer
generated from the crystal structural coordinates of the subunit in
the tetramer (38) using the program Molscript (69). Several of the
FAP causing mutations are found in the C-strand loop D-strand
region including the most lethal mutation L55P which is represented
by the black sphere in the D-strand.
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tural changes, while electron microscopy and sedimentation
velocity studies were employed to characterize self-assembly
mediated by acid and thermally induced partial denaturation.
The results demonstrate that L55P-TTR (0.2 mg/mL, 37 °C,
pH 7.0) slowly dissociates to the alternatively folded
amyloidogenic monomer that self-assembles into protofila-
ments under physiological conditions, a process which is
dependent on concentration, pH, and temperature. Impor-
tantly, studies on L55P-TTR amyloidogencity suggest a
common mechanism for TTR amyloid fibril formation and,
therefore, a common therapeutic strategy can be envisioned
for preventing fibril formation in the diseases SSA and FAP
(1, 16), even though L55P-TTR is drastically more amy-
loidogenic than WT-TTR.
MATERIALS AND METHODS
The silver staining kit used to visualize SDS-PAGE gels
was purchased from Pierce or Biorad. The detergent Z 3-14
was obtained from Calbiochem. The Congo red used in this
study was procured from Sigma and was recrystallized from
water/ethanol as described previously (31). All other reagents
used were of the highest quality available from Fisher, Sigma,
or Calbiochem and were used without further purification.
Expression and Purification of L55P (Met-1)-TTR. The
L55P (Met-1)-TTR variant was isolated and purified from
recombinant sources following the procedures described
below and developed by David Wemmer’s group (UC
Berkeley) (54). The L55P (Met-1)-TTR pMMHa plasmid
was transformed into competent BL21 DE3 Epicurian Gold
cells (Strategene). Two 1.5 L flasks of LB medium with
ampicillin (100 íg/mL) were innoculated with fresh 5 mL
overnight cultures. Cells were grown at 37 °C with vigorous
shaking until they reached an OD600nm of 0.6 (AU); they were
then induced with 2 mM IPTG. After 19 h of post-induction
agitation, the cells were harvested, resuspended in 25 mM
Tris buffer (pH 7.5, 2 mM EDTA, 0.1% (v/v) Triton X-100),
and lysed by two cycles of freeze-thaw, followed by
sonication (4  30 s). After removal of the cell debris by
centrifugation, L55P (Met-1)-TTR was ammonium sulfate
precipitated (50-90%). The pellet was resuspended in a
minimal volume of 25 mM Tris buffer, pH 8.0, and desalted
over a Hi-Prep desalting column (Pharmacia). The desalted
protein solution was heated at 60 °C for 30 min in order to
precipitate out contaminating proteins. The supernatant was
loaded onto a Source Q column (Pharmacia) and eluted using
a linear NaCl gradient (0.20-0.35 M NaCl) employing 25
mM Tris buffer, pH 8.0, affording 180 mg of >95% pure
TTR/3.0 L of liquid culture. An SDS-PAGE gel was utilized
to assess protein purity. Because of its tendency to aggregate
upon storage for more than two weeks (even at 4 °C),
purified L55P-TTR was always ammonium sulfate precipi-
tated (90%) and stored as a pellet at 4 °C. Dissolution of
the pellet and use of the sample within a few days yields
tetrameric L55P-TTR, according to ultracentrifugation analy-
sis (see below). To circumvent any complications caused by
the presence of soluble aggregates in L55P-TTR stock
solutions stored for more than a week, analytical ultracen-
trifugation methods were routinely employed with aged
samples to make sure that experiments commenced with a
hydrodynamically defined pure tetrameric protein (see
below). We have found that centrifugation of stock solutions
at 50 000 rpm (237000g, preparative Beckman centrifuge)
followed by filtration through 0.2 ím membranes is sufficient
to remove the vast majority of soluble aggregates in aged
L55P-TTR solutions.
EValuating the Extent of L55P-TTR Amyloid Fibril For-
mation. The extent of L55P-TTR amyloid fibril formation
mediated either by acid or thermal denaturation was evalu-
ated by turbidity or optical density (OD) measurements at
330 nm in a standard UV cell (55, 56). In addition, a Congo
red binding assay was utilized to quantify the amount of
amyloid fibrils formed (31, 57). Dissolution of an ammonium
sulfate pellet of L55P-TTR (10 mM phosphate buffer, pH
7.5, 100 mM KCl, 1 mM EDTA), desalting over a Hi-Prep
column (Pharmacia), and concentration of the sample results
in a stock solution (3-5 mg/mL). This solution was diluted
into 50 mM sodium acetate or sodium phosphate buffer (100
mM KCl) at the desired pH in a glass test tube to evaluate
the extent of amyloid fibril formation observed (final TTR
concentration ) 0.2 mg/mL). The resulting stagnant solutions
were incubated for 24 or 48 h at 37 °C. Prior to turbidity
evaluation (OD330nm) the samples were vortexed to equally
distribute the fibril suspension. To provide an independent
measurement of the amount of fibrils formed, 50 íL of the
L55P-TTR suspension was added to 1150 íL of a 10 íM
Congo red solution (5 mM phosphate, 150 mM NaCl, pH
7.5) and the absorbances of the suspension at 477 and 540
nm were recorded. The quantity of fibrils formed was
determined by the amount of Congo red bound to the amyloid
fibrils (characterized by a red-shifted absorbance) in solution
(mol of Congo red bound/L of amyloid suspension ) A540nm/
25 295 - A477nm/46 306) (57, 58).
Probing the Time Course of Amyloid Fibril Formation Via
Turbidity. The time course of amyloid fibril formation was
evaluated by monitoring the change in turbidity at 330 nm
as a function of time and pH (25 °C). Samples were prepared
by adding 120 íL of a L55P-TTR stock solution (5 mg/mL)
to 2.88 mL of 50 mM acetate buffer (100 mM KCl) at the
desired pH in a standard UV cuvette to afford a L55P-TTR
solution (0.2 mg/mL). The L55P-TTR solutions were placed
immediately into a Hewlett-Packard (Palo Alto, CA) UV
spectrophotometer (10 s dead time), and data collection was
initiated thereafter by monitoring the change in OD at 330
nm employing mechanical stirring.
Probing the Stability of the Tetrameric Leu-55-Pro
Structure Via SDS-PAGE. The quaternary structural changes
exhibited by L55P-TTR during acid denaturation were
probed using an SDS-PAGE method developed in our
laboratory (29, 31). SDS-PAGE analysis provides a fast and
reliable means for evaluating the amount of tetramer present
as it runs as a dimer on the SDS-PAGE gel (confirmed by
analytical ultracentrifuge studies), provided TTR is not boiled
in the SDS sample buffer (boiling results in the conversion
of the dimer band to a monomer band) (31, 33). However,
the SDS-PAGE method does not faithfully represent the
amount of monomer present due to the fact that soluble
aggregated forms of TTR dissociate into monomers in
nonboiled SDS-PAGE buffer (16, 33). Although dimeric
TTR could exist as a transient species, techniques such as
sedimentation velocity/equilibrium analysis and analytical gel
filtration, capable of resolving the TTR monomer, dimer,
and tetramer, do not detect dimeric TTR.
The L55P-TTR samples (0.2, 0.1, 0.01 mg/mL) were
incubated at 25 °C in 50 mM phosphate or acetate buffer to
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establish a monomer-tetramer equilibrium at the desired pH.
After incubation of the samples for 24 or 44 h, the detergent
Z 3-14 (from a 25 mg/mL stock Z 3-14 solution in water)
was added to each TTR solution (the zwitterionic detergent
Z 3-14 is used to prevent the refolding/reassociation of
monomeric TTR to the native tetramer during the neutraliza-
tion process necessary for gel loading) (31). Twenty íL of
0.6 M phosphate buffer (pH 7) containing 0.5 mg/mL Z 3-14
was added to TTR solutions to neutralize the pH. These
samples (20 íL) were mixed with 10 íL of 5% SDS sample
buffer in an Eppendorf tube and loaded without boiling onto
a 12% SDS-PAGE gel that was run and stained using
Gelcode Blue Staining Reagent (Pierce) or visualized by
silver stain (Biorad; for 0.01 mg/mL samples). The SDS-
PAGE gels were analyzed by a Molecular Dynamics model
(D1PC) computing densitometer and the band intensity data
were plotted versus pH to depict the ratio of L55P-TTR
tetramer to all other quaternary structural forms displayed
as monomer by SDS-PAGE analysis. The midpoint (pHm)
of the acid mediated tetramer to monomer/oligomer transition
is the pH at which half of the TTR is in the tetrameric form
by weight.
EValuating Amyloidogenic L55P-TTR Quaternary Struc-
tural Changes Via Analytical Ultracentrifugation. Sedimenta-
tion velocity experiments were utilized to assess sample
homogeneity/heterogeneity and the distribution of quaternary
structural species formed during acid and thermally induced
denaturation/amyloid fibril formation. Concentrated TTR
stock solutions (5 mg/mL, 10 mM phosphate, 100 mM KCl,
1 mM EDTA) were spun on a desktop centrifuge (16000g)
for 15 min at 4 °C and all buffers were filtered through a
0.22 ím filter before they were subjected to incubation.
Transthyretin solutions (0.2 or 0.05 mg/mL) were prepared
by dilution of the centrifuged TTR stock solution into a
filtered buffer (50 mM phosphate or acetate buffer, 100 mM
KCl) at the desired pH and temperature (4, 25, or 37 °C).
The sedimentation properties of TTR as a function of pH,
temperature, concentration, and incubation time were ob-
tained from velocity data collected on a temperature-
controlled Beckman XL-I analytical ultracentrifuge (equipped
with a An60Ti rotor and photoelectric scanner). A double
sector cell, equipped with a 12 mm Epon centerpiece and
quartz windows, was loaded with 400-420 íL of sample
using a blunt-end microsyringe. Data were collected at rotor
speeds of 3000-60 000 rpm in continuous mode at 4 or 20
°C, with a step size of 0.005 cm employing an average of
1-4 scans per point. The data were subjected to analysis
using the Svedberg direct boundary fitting approach (for
samples containing up to 3 components) to allow for MW
determination using the sedimentation coefficient and dif-
fusion coefficient obtained from the appropriate fitting model
(59). For samples containing a heterogeneous mixture of
quaternary structural species, the van Holde and Weischet
direct fitting and the time derivative (dc/dt) methods were
used to analyze the distribution of species in solution
represented by a range of s values (16, 60-62).
Sedimentation Equilibrium Experiments. Sedimentation
equilibrium experiments allow the quaternary structural
changes required for amyloid fibril formation to be studied
provided that the heterogeneity is limited to two species or,
alternatively, four associating species that are in equilibrium.
A TTR sample (150 mL) in a double sector cell with a
charcoal-filled Epon centerpiece and sapphire windows at
the desired pH and temperature was analyzed using rotor
speeds from 3000-17 000 rpm. All scans were performed
at 280 nm (230 nm at lower concentration), with a step size
of 0.001 cm, employing 25 averaged scans. Samples were
allowed to equilibrate for 24 h, and duplicate scans 3 h apart
were overlaid to determine that equilibrium had been reached.
The data were analyzed by nonlinear least-squares analysis
in the Origin software provided by Beckman (Palo Alto, CA)
as described in detail previously (16).
EValuating L55P-TTR pH-Dependent 2′ and 3′ Structural
Changes by Far- and Near-UV Circular Dichroism. Circular
dichroism (CD) spectroscopy was used to further evaluate
the secondary and tertiary structural requirements for L55P-
TTR amyloid fibril formation (acid-induced). The CD spectra
of L55P-TTR as a function of pH were recorded on an Aviv
Model SF202 spectrometer (25 °C). Transthyretin solutions
at 0.01 mg/mL (a concentration where aggregation is not a
problem) at the desired pH (50 mM acetate or phosphate
buffer, 100 mM KCl) were prepared by dilution of a 5 mg/
mL stock solution (10 mM phosphate, 100 mM KCl, and 1
mM EDTA). CD studies carried out at 0.01 mg/mL were
performed using 0.2 cm quartz cell for far- (195-250 nm)
and a 10 cm quartz cell for near-UV CD (250-320). A step
size of 0.2 nm, an averaging time of 3 s and an average of
15 scans were recorded to generate the data reported in units
of mean residue ellipticity. The far- and near-UV CD data
were smoothed using a Stineman function (KalidaGraph
software), which reduced the noise without perturbing the
appearance of the data.
EValuating the Tertiary Structural Changes Exhibited by
L55P-TTR during Acid Denaturation Via Fluorescence
Spectroscopy. The tertiary structural changes occurring
during L55P-TTR acid-induced denaturation/amyloid fibril
formation were evaluated by monitoring the changes in the
intrinsic tryptophan fluorescence of L55P-TTR as a function
of pH at a concentration where self-assembly is not competi-
tive. The L55P-TTR samples (0.01 mg/mL) were made by
adding 10 íL of a L55P-TTR stock solution (1 mg/mL) to
the desired buffer solution (990 íL of 50 mM acetate or
phosphate, 100 mM KCl). Fluorescence spectra of L55P-
TTR as a function of pH were recorded on Aviv model ATF
105 spectrofluorometer at 25 °C in a 1 cm quartz cell. The
excitation wavelength was set at 295 nm (slit width of 4
nm) and the emission wavelength monitored at 340 nm (slit
width of 8 nm) to measure the tryptophan fluorescence
exclusively.
ANS Binding as a Probe of Denaturation. ANS binding
studies were employed to evaluate the relative hydrophobicity
of the amyloidogenic intermediate formed under acidic partial
denaturing conditions. A stock ANS solution (5.6 mM) was
prepared, and its concentration determined by absorbance
at 351 nm ( ) 6240 M-1 cm-1). To measure the binding of
ANS to L55P-TTR as a function of pH, 3 mL of a 0.01 mg/
mL TTR solution in the appropriate buffer was prepared and
equilibrated at 25 °C for 20-28 h. An aliquot of an ANS
stock solution was then added to afford a final ANS
concentration of 48 íM. The resulting solutions were further
incubated at 25 °C for another 24 h prior to recording the
fluorescence spectra. The fluorescence intensities were
measured via excitation at 410 nm, recording emission at
490 nm.
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Probing the Assembly of the L55P-TTR Amyloidogenic
Intermediate by Electron Microscopy and Dye Binding.
Electron microscopy was utilized to evaluate the nature and
structure of the L55P-TTR aggregates formed as a function
of pH, temperature, and ionic strength. Imaging was enabled
by placing 5 íL of the sample on a carbon-coated copper
grid, allowing the solution to stand for 2 min before removing
excess solution. The grid was then washed once with distilled
water and once with 1% uranyl acetate before staining the
sample with fresh 1% uranyl acetate for another 2 min.
Excess uranyl acetate was blotted with Whatman filter paper.
The samples were then evaluated using a Phillips CM-100
(100 kV) electron microscope. The grid was thoroughly
examined to obtain an overall sense of the structures present
in the sample. The protofilaments formed at pH 7.5 were
evaluated by thioflavin T and Congo red binding. For
thioflavin T binding studies, 100 íL of 0.2 mg/mL L55P-
TTR solutions, containing protofilaments, were added to 500
íL of a 10 íM thioflavin T solution in PBS buffer (pH 6.6).
The fluorescence intensities were measured via excitation
at 450 nm and the emission spectra was recorded from 460
to 630 nm. Congo red binding analysis was performed as
described previously (29).
RESULTS
EValuating the Extent of L55P-TTR Acid Denaturation-
Amyloid Fibril Formation. The extent of L55P-TTR amyloid
fibril formation (protofilament and filament formation) as a
function of pH (37 °C) was evaluated by monitoring turbidity
(330 nm) and quantitative Congo red binding of the amyloid
suspension, employing stagnant solutions to form the fibrils
in both cases (Figure 2A). Congo red binding also establishes
the amyloid-like structure of the aggregates. The extent of
L55P-TTR fibril formation observed at 48 h (Figure 2A) was
generally greater than that observed at the 24 h time point,
Figure 2B. Amyloid fibril formation (L55P-TTR) reached a
plateau at 72 h for all suspensions evaluated over the pH
range of 4.2-5.2, making it difficult to identify the pH
maximum at that time point (data not shown). Unlike wild-
type TTR, which exhibits maximum amyloid fibril formation
at pH 4.4, L55P-TTR exhibits its maximum rate at pH 5.0.
In addition, the extent of L55P-TTR amyloid fibril formation
near physiological pHs (5.5-7.0) is much greater than that
exhibited by wild-type TTR. As expected, good agreement
was observed when comparing turbidity measurements and
the Congo red binding as a measure of the extent of amyloid
fibril formation, Figure 2, A and B.
The time course evaluation of the early stages of L55P-
TTR amyloid fibril formation as a function of pH revealed
that amyloid fibril formation is significantly faster at pH 5.0
than at pH 5.25 or 4.4, as detected by turbidity, Figure 2C.
It is important to realize that turbidity measurements do not
detect small soluble assemblies that could artificially produce
a lag phase even though self-assembly is occurring from the
beginning, which is the case according to sedimentation
velocity studies (16). The data shown in Figure 2C was
acquired using a stirred assay, unlike the unstirred data shown
in Figure 2A, B.
The L55P-TTR variant did not exhibit turbidity below pH
3.0 (330 nm) suggesting the absence of large insoluble
aggregates, Figure 2, A and B. However, Congo red binding
was observed after incubation of TTR below pH 3.0 (Figure
2, A and B), suggesting the presence of smaller oligomers,
at least some of which have an amyloid-like structure. The
apparent discrepancy between the Congo red binding and
the turbidity assays at lower pHs can be readily reconciled
because the quaternary structures formed below pH 3 are
small and, therefore, not expected to exhibit turbidity as
discerned from sedimentation velocity studies (s ) 4-11 S
(see below and Table 1; entry 11) (16).
EValuating L55P-TTR Quaternary Structural Changes by
Analytical Ultracentrifugation. Sedimentation equilibrium
and velocity studies on L55P-TTR as a function of pH,
FIGURE 2: Bar graph depicting the extent of L55P-TTR fibril
formation after 48 h (A) and 24 h (B) as a function of pH. The
black bars represent the OD measurements while the light bars
represent the extent of fibril formation based on a quantitative
Congo red determination. (C) The time course of L55P-TTR self-
assembly into protofilaments and filaments (0.2 mg/mL) as a
function of pH (5.25, 5.0 and 4.4) at 25 °C monitored by turbidity
(330 nm). This experiment demonstrates that L55P-TTR exhibits
the maximal rate of fibril formation at pH 5.0.
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temperature, and concentration reveal that L55P-TTR adopts
a stable tetrameric structure over the physiological concen-
tration range (25 °C, pH 7) when incubated in solution for
less than 4 days, Table 1; entry 1. Sedimentation equilibrium
results on L55P-TTR demonstrate that the tetramer starts to
dissociate to monomer within 24 h, yielding a tetramer-
monomer equilibrium at a concentration an order of mag-
nitude below physiological (0.02 mg/mL, pH 7), Table 1;
entry 2. Velocity studies on L55P-TTR at physiological
concentrations (0.2 mg/mL) incubated at pH 7 (37 °C) for
>8 weeks reveal that the protein does slowly dissociate to
monomer, which then assembles into protofilaments under
these conditions, the oligomers having s values ranging from
2 to 23 S, Table 1; entry 3. To demonstrate that L55P-TTR
protofilament formation (0.2 mg/mL) likely occurs through
the assembly of a monomeric amyloidogenic intermediate,
sedimentation velocity experiments were carried out at pH
7 after incubation for 4 days at 37 °C. The sedimentation
velocity profiles reveal the presence of two resolvable
boundaries in Figure 3A, each curve representing data as a
function of time during sedimentation of the sample. Direct
fitting of the sedimentation velocity profiles gives an
excellent fit to a two species model with sedimentation
coefficients and molecular weights that correspond to the
L55P-TTR tetramer (s1 ) 3.7, 53 KDa, 90%) and monomer
(s2 ) 1.2, 13 KDa, 10%). The appropriateness of the fit is
demonstrated by the random residuals and the small standard
deviations of (0.015 AU shown in Figure 3B. Attempts to
fit the data to a single ideal species model of tetramer, dimer,
or monomer failed to give a good fit.
Incubation of L55P-TTR (pH 7) in the cold (4 °C) at
concentrations g0.2 mg/mL also leads to tetramer dissocia-
tion affording a monomer that assembles into protofilaments,
Table 1; entry 5. The sedimentation velocity profiles of a
L55P-TTR sample (0.2 mg/mL) prepared from a 2 mg/mL
stock solution that was stored at 4 °C for 3 weeks shows
two resolvable boundaries; a fast sedimenting boundary that
corresponds to protofilaments and a slow moving boundary
that corresponds to a mixture of tetramer and monomer
(Figure 4A). The protofilaments formed after 1-4 weeks (4
°C) constitute only 10-25% of the total protein content of
the sample (absorbance analysis). The slow sedimenting
boundary is composed predominantly of tetramer (3.75 S)
and some monomer (1.4 S) 5-8%, Figure 4B. Inclusion of
the monomer in the fitting model was necessary to obtain a
good fit for the data as determined by comparing the residuals
from the fit to various models.
The L55P-FAP variant dissociates and self-assembles
much faster over the pH range of maximal amyloid formation
(pH 5.25-5.0; 25 °C, Figure 2) and within the time frame
of the sedimentation velocity experiment (2-4 h), complicat-
ing data analysis and thus precluding an accurate evaluation
of the quaternary structural species present in solution, Table
1; entry 6. Quaternary structural analysis by sedimentation
velocity studies over this pH range were made possible by
incubating the samples at 4 °C for 4 h. Velocity analysis
reveals that L55P-TTR (pH 5.25, 4 °C) exists as a mixture
of tetramer (s ) 3.7 S, 91%) and monomer (1.4 S, 9%),
Table 1; entry 7. Sedimentation velocity analysis of L55P-
TTR (0.2 mg/mL), incubated at pH 5.0 (4 °C) for 12 h,
demonstrates the presence of a heterogeneous mixture of
oligomeric species sedimenting with a distribution of sedi-
mentation coefficients ranging from 2 to 9 S, Table 1, entry
8. Sedimentation velocity studies of L55P-TTR under more
acidic conditions (pH 4.4, 4 °C) reduces the rate of
aggregation, allowing the detection of a ladder of quaternary
structure intermediates with s values ranging from 4 to 13
S; consistent with results reported previously for L55P-TTR
(16), Table 1, entry 9.
To probe whether the monomeric amyloidogenic inter-
mediate is in equilibrium with the functional tetramer or
oligomers under acidic amyloid forming conditions, sedi-
mentation equilibrium studies were carried out at lower TTR
concentrations (0.02 mg/mL) at 4 °C to reduce the extent of
self-assembly to protofilaments and fibrils. Attempts to fit
sedimentation equilibrium data for L55P-TTR (0.02 mg /mL,
4 °C, pH 5.0) to a single ideal species model failed to give
a good fit. However, an excellent fit was obtained to these
Table 1. Summary of Analytical Ultracentrifugation Experiments Carried Out with L55P-TTR as a Function of pH, Temperature, and
Concentrationa
entry pH
temp.
(°C)
incubation
time
concentration
(mg/mL)
s values and MW by
sedimentation velocity
MW by
sedimentation
equilibrium best fitting model
1 7 25 1-4 days 0.2-1.0 3.6-3.7 S (52-55 KDa) 53 KDa tetramer
2 7 25 20-24 h 0.02 55 KDa, 13 KDa tetramer, monomer
3 7b 37 >8 weeks 0.2 2-23 S 90% soluble oligomers
4 7c 37 2-8 weeks 0.2 visible aggregates, 2-9 S, 3.7 S, 1.2 S soluble oligomers, tetramer, monomer
5 7d 4 g2 weeks 0.2 9 S, 3.7 S (51 KDa), 1.2 S (13.8 KDa) 20% oligomers and 80% (tetramer, monomer)
6 5.25-4.4e 25 20-24 h 0.2 extensive visible aggregation
7 5.25f 4 4 h 0.2 3.7 S (54 KDa), 1.4 S (14 KDa) tetramer, monomer
8 5 4 12 h 0.2 2-9 S soluble oligomers
9 4.4 4 24 h 0.2 4-13 S soluble oligomers
10 5 4 24 h 0.02 55, 13.8 KDa tetramer, monomer
11 3.0-2.0g,h 4,25 months 0.2 4-11 S 14-260 KDa A “state” like oligomers
aThe L55P molecular weight under various conditions was determined by sedimentation equilibrium and/or sedimentation velocity (MW is calculated
based on the diffusion coefficient values obtained by direct fitting of the data using Svedberg 5.0, which employs the following equation to calculate
MW ) sRT/D(1-øjF). Samples were incubated at the indicated temperatures, but all sedimentation velocity experiments were carried out at 20 °C.
b Reference 16. cThe amount of monomer left in solution increases with increasing incubation time and is highly dependent on salt (KCl) concentrations,
with monomer making up 40-40% of the remaining soluble protein in samples that show extensive aggregation at pH 7 (37 °C). d Samples incubated
at 4 °C did not show any turbidity even after 4 weeks of incubation. e Extensive aggregation and protein precipitation during the time scale of the
analytical ultracentrifuge experiments precluded an accurate analysis of the data under these conditions. f Sedimentation equilibrium data fits well
only to a monomer-tetramer associating model for TTR; furthermore, the MW vs concentration plot shows a MW distribution of 17-46 KDa.
g L55P forms soluble protofilaments that do not go on to form fibrils, even after incubation for months in vitro. h L55P TTR is monomeric over the
pH range 2-3, in the absence of added KCl.
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data using an associating monomer (13.8 KDa)-tetramer (55
KDa) equilibrium model as judged by the residuals, Figure
5, Table 1, entry 10. The L55P-TTR variant, like the wild-
type protein, assembles into small oligomeric structures over
the pH range of 3.0-2.0, with sedimentation coefficients
ranging from 4 to 11 S, Table 1; entry 11.
EValuating L55P-TTR Quaternary Structural Changes by
SDS-PAGE Analysis. Evaluation of the SDS-PAGE moni-
tored L55P-TTR quaternary structure changes (0.2 mg/mL)
as a function of pH is shown in Figure 6. The results
demonstrate that L55P-TTR is predominantly tetrameric
(runs as a dimer band) from pH 7.0 to 5.5, Figure 6A. The
L55P-TTR tetramer (pH 7.0) is capable of undergoing slow
dissociation to a monomer after 44 h of incubation at 37
°C, as evident by the presence of a faint monomer band
(<10%) in the SDS-PAGE gel of the nonboiled TTR samples
(0.2 mg/mL), Figure 6A. Below pH 5.0, the L55P-TTR
monomer was the predominant species (90-95%), with
complete tetramer to monomer dissociation observed below
pH 3.8, Figure 6A. It is noteworthy that the monomeric band
shown at pHs below 5.0 represents both L55P-TTR monomer
and any SDS sensitive oligomeric species formed (16, 31).
To evaluate whether the L55P-TTR tetramer-monomer
transition observed over the pH range of 5-5.5 exhibits a
concentration dependence, the quaternary structural changes
were probed at three TTR concentrations, 0.2, 0.1, and 0.01
mg/mL, Figure 6B. At 0.2 and 0.1 mg/mL, L55P-TTR
exhibited similar acid dissociation transitions, with the L55P
tetramer being the major species (>80%) above pH 5.5,
below pH 5 the L55P monomer becomes the major species
(>90%). Interestingly, at a concentration of 0.01 mg/mL, a
significant fraction of the L55P-TTR tetramer had dissociated
to monomer (40%, incubation time ) 44 h) above the pH
range over which the acid mediated transition takes place
(5.5-5) Figure 6, B and C, whereas L55P-TTR is predomi-
nantly tetrameric at physiological concentration (0.2 mg/mL)
above pH 5.5. The results in Figure 6B demonstrate that the
pHm (5.18) at all three concentrations (0.2, 0.1, 0.01 mg/
mL) was virtually identical, demonstrating that the tetramer-
monomer transition induced by acid denaturation is not very
sensitive to TTR concentration, whereas the tetramer-
monomer equilibrium above pH 5.5 is quite sensitive to
FIGURE 3: (A) Sedimentation velocity profiles of L55P-TTR (0.2
mg/mL, pH 7) incubated for 4 days at 37 °C. Scans for analysis
were recorded every 3 min; for clarity, only 8 representative scans
15 min apart are shown. The solid line represents the two-species
fit (tetramer and monomer) to the experimental data (O) using the
Svedberg program. The inset in Figure A identifies the two
sedimenting boundaries corresponding to the L55P-TTR tetramer
and monomer. (B) The residuals (difference between the experi-
mental data and the fitted data for each data point) for the two
species fit. The overall root-mean-square deviation for the data is
0.015 absorbance units.
FIGURE 4: (A) Sedimentation velocity profiles of L55P-TTR (0.2
mg/mL) prepared by dilution from a stock solution of 2 mg/mL
that was incubated at 4 °C for 4 weeks. The velocity data exhibits
two resolvable boundaries, one corresponding to a mixture of
soluble oligomeric species (amyloid precursors), with the second
boundary corresponding to a mixture of predominantly L55P-TTR
tetramer and 5-8% monomer. (B) Direct fitting of the slow
sedimenting boundary to a two species model of tetramer and
monomer yields the two-species fit (solid line) to the experimental
data (O) using the Svedberg program.
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concentration. A time course evaluation of the L55P-TTR
tetramer-monomer equilibrium at pH 7 by SDS -PAGE
analysis (0.2 and 0.01 mg/mL) reveals no detectable changes
in the amount of tetramer or monomer for incubation periods
between 44 and 60 h (data not shown).
Monitoring Acid-Induced Denaturation of L55P-TTR by
Fluorescence Spectroscopy. TTR amyloid fibril formation
from the monomeric amyloidogenic intermediate is a con-
centration-dependent process that competes with denaturation
at concentrations above 0.05 mg/mL. Hence, pH-dependent
fluorescence experiments to monitor tertiary structural
changes were carried out at a concentration of 0.01 mg/mL,
to prevent assembly of the amyloidogenic intermediate (fibril
formation). Interestingly, L55P-TTR exhibits a biphasic acid-
mediated unfolding transition as monitored by tryptophan
fluorescence (excitation at 295 nm), Figure 7A. Over the
pH range of 7.0-5.5, the fluorescence intensities exhibited
a slight fluctuation, but no significant change in the intensity,
Figure 7A. From pH 5.5-5.0, the first transition was
observed, which is likely the result of a linked quaternary
and tertiary structural transition (pH-dependent quaternary
structural changes are displayed in Figure 7A) to form the
amyloidogenic intermediate. The fluorescence intensity of
the tryptophans at pH 5.0 appeared to vary from one data
set to another for reasons that remain unclear, but the overall
shape of the acid-induced denaturation curve remains the
same as indicated by the error bars for all data points (4
data sets) (see discussion). Over the pH range of 4.75-4.0,
a slight increase in fluorescence intensity was observed
followed by a plateau region from pH 4.0-3.5. It is unclear
whether the dip at pH 5 is significant; what is clear is that
the conformers populated over this pH range are amy-
loidogenic, Figure 2. Lowering the pH through the range of
3.5-2.5 results in a second structural transition detected by
fluorescence reflecting a transformation from the amy-
loidogenic intermediate(s) to a molten globule “A state”, as
discerned by ANS binding (see below), Figure 7A. This state
is monomeric at low concentrations (0.01 mg/mL), but exists
as an oligomer at higher concentrations (0.2 mg/mL) as
discerned from its sedimentation properties evaluated previ-
ously (16, 31). At pH 3.0, the emission maximum exhibited
a red shift from 337 to 342 nm indicating that the tryptophan
residues in L55P-TTR are more, but not completely, exposed
to solvent, Figure 7B. At pH 2, the fluorescence emission
maximum showed a significant red shift to 355 nm and the
fluorescence intensity decreased dramatically, most likely due
to dynamic quenching as a result of further exposure of the
side chains (unfolding) and increased side chain mobility,
Figure 7B.
ANS Binding Monitoring Hydrophobic Surface Exposure.
The fluorescence emission of ANS does not exhibit pH-
dependent behavior, therefore, any changes in the fluores-
cence spectra of ANS as a function of pH are a result of
binding to exposed hydrophobic surfaces of L55P-TTR. It
is known that two moles of ANS bind to the central thyroid
binding channel of the WT-TTR tetramer, providing an
internal stoichiometry calibration (63). Binding of ANS to
the WT-tetramer is reported by an increase in ANS fluores-
cence as well as by a blue shift in the fluorescence emission
maximum (31). ANS binding to L55P-TTR as a function of
FIGURE 5: Sedimentation equilibrium analysis of L55P-TTR (0.02
mg/mL) in 50 mM acetate buffer, pH 5.0 (4 °C). The solid line
drawn through the data (o) was obtained by fitting the absorbance
vs radial position data using a self-associating model for a
monomer-tetramer equilibrium. The inset bar graph represent the
residuals (difference between the experimental data and the fitted
data for each point).
FIGURE 6: Concentration dependent quaternary structural changes
in L55P-TTR as a function of pH (A) SDS-PAGE gel from which
the L55P-TTR acid denaturation curve in Figure 6B was derived
(0.2 mg/mL). (B) Tetramer-monomer transition as a function of
pH for L55P-TTR at 0.2 mg/mL (4), 0.1 mg/mL (0) and 0.01
mg/mL (O) after incubation for 40 h at 37 °C. (C) SDS-PAGE
gel for L55P-TTR acid denaturation at 0.01 mg/mL employing
smaller pH increments (0.25 pH unit steps).
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pH is shown in Figure 8. Over the pH range of 7-6, ANS
binding to the L55P-TTR tetramer is either very weak or it
does not occur, Figure 8A. This can be rationalized because
L55P-TTR exhibits a decreased affinity (10) for TTR
ligands, and furthermore, only 60% of L55P-TTR is tet-
rameric at this concentration and pH, Figure 6 (23, 64). The
fluorescence emission spectrum of ANS in the presence of
L55P-TTR at pH 5.0 (520 nm) (pHmax for amyloid fibril
formation) is equivalent to that exhibited by ANS alone in
aqueous buffer, Figure 8B, consistent with the idea that the
alternatively folded monomeric amyloidogenic intermediate
formed does not bind to ANS. This behavior is similar to
that of wild-type TTR, which exhibits a pHmax for fibril
formation and a minimum in ANS binding at pH 4.4 (31).
Below pH 5.0, ANS binding to L55P-TTR increases linearly
with the decrease in pH (Figure 8), suggesting increased
exposure of the hydrophobic surface as a likely result of a
tertiary structural rearrangements in the L55P-TTR mono-
meric amyloidogenic intermediate, Figure 7, A and B. ANS
fluorescence reached a maximum at pH 1.5 where the
monomer is largely unfolded.
Far and Near-UV CD of L55P-TTR as a Function of pH.
The pH-dependent conformational changes that allow L55P-
TTR amyloid fibril formation were probed by far- and near-
UV CD studies at a concentration where assembly is not
problematic (0.01 mg/mL). The pH-dependent far-UV CD
spectra of L55P-TTR shown in Figure 9A reveal that the
secondary structural changes taking place under amyloid
fibril formation conditions are subtle. At pH 7 (native
conditions), the far-UV CD of L55P-TTR exhibited a signal
that is characteristic of â-sheet structure with a minimum at
214 and a maximum at 195 nm. Upon lowering the pH to
5.0, the far-UV CD minimum for L55P-TTR does not
change; however, a significant change in the maximum (195
nm) intensity was observed (no detectable turbidity), Figure
9A. Although the amplitude of the two observable CD signals
for â-sheet structure are dependent on sheet length, orienta-
tion, and twist, the absence of the maximum band at 195
nm in the far-UV CD signal may reflect a secondary
structural rearrangement within the L55P-TTR monomer,
leading to the formation of the monomeric amyloidogenic
intermediate. This intermediate, which is significantly popu-
lated at pH 5.0, leads to maximal fibril formation at
physiological concentration (0.2 mg/mL), Figure 2. Over the
pH range of 4-3, L55P-TTR exhibits a broad and more
intense minimum at 214 nm, indicating further secondary
structural changes. The L55P-TTR (0.01 mg/mL) minimum
at 200 nm at pH 2 in both the presence and absence of salt
is consistent with a largely unordered ensemble of structures,
Figure 9A.
The near-UV CD spectra of L55P-TTR, resulting from
the asymmetric packing of the tryptophan and tyrosine side
chains, revealed significant pH-dependent tertiary structure
changes, Figure 9B. The near-UV signals from the tryptophan
FIGURE 7: (A) Acid denaturation curve of L55P-TTR (0.01 mg/
mL) monitored by changes in the tryptophan fluorescence intensity
([) at 340 nm (excitation at 295 nm). The pH dependent
equilibrium between tetramer and monomer as evaluated by the
SDS-PAGE method is shown (b) to assist interpretation. (B)
Tryptophan emission spectra of L55P-TTR (0.01 mg/mL) as a
function of pH (excitation at 295 nm).
FIGURE 8: (A) Summary of ANS binding monitored by fluorescence
emission at 490 nm as a function of pH, error bars are shown to
represent the standard deviation for 4 data sets. (B) ANS (48 íM)
binding to L55P-TTR (0.01 mg/mL) as a function of pH monitored
by ANS fluorescence (excitation at 410 nm) emission at 490 nm.
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and tyrosine side chains at pH 7 and 6 are not significantly
different, in agreement with the far-UV data and consistent
with the absence of significant Trp fluorescence changes over
this pH range. Near-UV CD change was observed at pH 5.0
where a significant decrease in intensity of the near-UV CD
signal for both tryptophan (292 nm) and tyrosine (284 nm)
residues was detected, consistent with the formation of the
amyloidogenic intermediate, Figure 9B. At pH 4.0, the near-
UV CD signal for both tryptophan and tyrosine residues
decreased further, consistent with the further tertiary struc-
tural rearrangement. Over the pH range of 4.0-3.0, the
tryptophan near-UV CD is diminished further and the spectra
exhibits a broad minimum around 275 nm, suggesting that
L55P-TTR adopts a less ordered tertiary structure at this pH.
At pH 2.0, a dramatic change was observed in the near-UV
CD spectra, consistent with a more unfolded structure (data
not shown). These results suggest a tertiary structural change
in L55P-TTR occurring over the pH range of 6-5, with an
additional modest tertiary structural change between pH 5-4,
followed by a significant tertiary structural change when the
pH is lowered further toward pH 2.0, Figure 9B.
Electron Microscopy to Follow the Assembly of the
Amyloidogenic Intermediate. Blake and co-workers have
previously shown that TTR amyloid fibrils isolated from the
vitreous humor of the eye are uniform, straight, and un-
branched fibers of approximately 100-130 Å in diameter
by electron microscopy (39). A single transthyretin amyloid
fibril is made up of four filaments, each having a charac-
teristic cross-â repeat structure that is about 50-60 Å in
diameter. The observation of smaller oligomeric intermedi-
ates during the process of transthyretin amyloid formation
in vitro was not reported until recently (16). The presence
of oligomeric, putative amyloid fibril precursors has also
been detected in Aâ fibrillogenesis by several groups (15,
17, 18, 20, 65). The dependence of L55P-TTR protofilament
formation on solution conditions, such as ionic strength, pH,
and temperature, was evaluated here. Briefly, these studies
reveal the formation of L55P-TTR protofilaments after 1
week of incubation at 37 °C (pH 6.0-7.5, 0-200 mM KCl).
Protofilament formation was less efficient at pH 6.0 than
over the pH range of 6.5-7.5. An electron microscopy time
course study at pH 7.5 (37 °C) demonstrates that L55P-TTR
is initially tetrameric, exhibiting an average diameter of 50-
55 Å (Figure 10A). After 1 week of incubation, a slow
conversion of the tetramer into monomer (37 Å diameter)
and finally into protofilaments having an average diameter
of 60-65 Å, with an average length of 50 nm (Figure 10B)
is observed. These short protofilaments elongate slowly (1-
1.5 months) generating protofilaments with an average length
of 110 nm, Figure 10C. The L55P-TTR protofilaments bind
thioflavin T and Congo red, albeit more weakly than do
fibrils formed under acidic conditions.
DISCUSSION
Wild-type transthyretin amyloid fibril formation appears
to require tetramer dissociation to an alternatively folded
monomer (amyloidogenic intermediate), which then self-
assembles into numerous quaternary structural intermediates
(protofilaments and filaments), ultimately affording amyloid
fibrils (1, 22, 31, 33). Studies described in the previous
section demonstrate that the familial amyloid polyneuropa-
thy-associated variant L55P also requires tetramer disas-
sembly and subtle conformational changes within the mon-
omeric subunit to be competent to undergo self-assembly
(16, 29, 30, 52, 66). Several biophysical methods, including
analytical ultracentrifugation studies, are able to detect L55P
self-assembly when the monomer is also detected in solution,
but self-assembly (amyloid formation) is not observed when
the tetramer is exclusively populated. The dimeric form of
transthyretin has not been detected in significant amounts
(<3%) in the case of WT-TTR or the FAP-associated
variants studied thus far under conditions where amyloid
fibril formation is also observed, suggesting that either the
tetramer directly dissociates to monomer or that the dimer
does not build up to a detectable concentration (16).
Dissociation of the WT-TTR tetramer to monomer is not
observed under physiological conditions (0.2 mg/mL, pH 7).
In contrast, L55P-TTR slowly dissociates from its tetrameric
structure, yielding a monomer under physiological conditions
(pH 7, 37 °C. 0.2 mg/mL) that subsequently self-assembles
into protofilaments, Figure 11. The activation barrier for
L55P-TTR dissociation is accessible under physiological
conditions in vitro (Figure 3), whereas the dissociation barrier
for WT and V30M TTR are not surmountable on a
biologically relevant time scale at 37 °C ([TTR] ) 0.2 mg/
mL) (66).
It appears that two different mechanisms of L55P-TTR
tetramer dissociation are operational for affording the L55P-
TTR monomeric amyloidogenic intermediate, i.e. there are
concentration and pH-dependent pathways. The tetramer-
monomer equilibrium is dependent upon concentration above
pH 5.5; a concentration an order of magnitude below
FIGURE 9: Conformational changes exhibited by L55P-TTR (0.01
mg/mL) monitored by far-UV CD (A) and Near-UV CD (B) as a
function of pH. Samples (0.01 mg/mL) were incubated for 2-6 h
at 4 °C prior to collecting data to prohibit aggregation.
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physiological (0.01 mg/mL) affords 40% L55P-TTR mono-
mer, whereas 15% monomer is observed for wild-type TTR
under these conditions (31). At physiological concentration
(0.2 mg/mL), L55P-TTR is greater than 97% tetrameric (pH
7, 25 °C, <96 h). The effect of pH on the L55P-TTR
tetramer-monomer equilibrium is dramatic over the range
of 5.5 to 5. A pH of 5 nearly completely dissociates the L55P
tetramer, a pH that does not dissociate the WT-TTR tetramer.
The protonation of one or more carboxylate or imidazole
side chains with an apparent pKa of 5.18 mediates a likely
conformational change that efficiently orchestrates L55P-
TTR tetramer dissociation, Figure 6. The pH-mediated
tetramer dissociation is largely independent of TTR concen-
tration, except for the fact that the TTR concentration sets
the pretransition tetramer/monomer ratio. The fact that
maximal amyloid fibril formation is observed at pH 5, where
the monomer is maximally populated and structured, is
consistent with the importance of the monomeric amyloido-
genic intermediate in amyloid fibril formation.
Evidence for a defined, but alternatively folded L55P-TTR
monomeric amyloidogenic intermediate is quite strong. Two
pH-mediated tertiary structural changes monitored by fluo-
rescence are detected at a concentration where self-assembly
is minimal, Figure 7. The first linked quaternary and tertiary
structural transition, pHm 5.18, yields the amyloidogenic
intermediate, while the second tertiary structural transition
centered around pH 3.25, clearly destroys the structure
required for self-assembly and ultimately amyloid fibril
formation, Figures 2 and 7. It is interesting that the
fluorescence data point at pH 5, the pH of maximal amyloid
fibril formation, exhibits variability. This experiment has
been repeated several times with the standard deviation
shown in Figure 7. Possibilities for the considerably larger
standard deviation than for other data points include the fact
that the tetramer-monomer equilibrium and the tertiary
structural change populating the amyloidogenic intermediate
are linked and appear to be hypersensitive to conditions at
this pH. There also may be variable amounts of assembly
occurring at pH 5 that we simply cannot detect, likely due
to the isoelectric point for the L55P-TTR monomer being
very close to this pH. Undoubtedly, this variability is telling
us something about the monomeric amyloidogenic interme-
diate, though we cannot fully appreciate its meaning at this
time. The pH range over which the acid dissociation
transition (pHm ) 5.18) observed for L55P-TTR takes place
is much narrower than that reported previously, likely due
to the presence of undetected soluble L55P-TTR oligomers
in the protein stock solutions used for earlier studies (30).
There may well be an additional tertiary structural transi-
tion occurring over the pH range of 5-4.25, i.e. the
amyloidogenic intermediate may be in equilibrium with a
more disordered structure. This hypothesis is supported by
considering both the far- and near-UV CD spectra that exhibit
modest changes when the pH is dropped below 5 and more
dramatic changes at pH 4, Figure 9. The increased ANS
binding (fluorescence) over the pH range of 5 (maximal fibril
formation) to 4 (reduced fibril formation) also supports a
conformation change associated with increased hydrophobic
exposure. The fluorescence transition associated with de-
struction of the amyloidogenic intermediate centered around
pH 3.25 exposes significant hydrophobic surface area as
discerned from ANS binding, Figure 8 (67).
From a comparison of the tetramer stabilities of WT-TTR
to the FAP-associated variants V30M and L55P, it is clear
FIGURE 10: (A) Electron micrograph of L55P-TTR after 24 h of
incubation under simulated physiological conditions (0.2 mg/mL,
100 mM KCl, pH 7.5, 37 °C) in vitro representing predominantly
L55P-TTR tetramer (having a diameter of 50-55 Å) and <3%
monomer (see Table 1), exhibiting a diameter of 37 Å (B) Electron
micrograph of L55P-TTR (0.2 mg/mL, 100 mM KCl, pH 7.5)
incubated at 37 °C for 1 week revealing abundant quantities of
short assembled L55P-TTR protofilaments having an average
diameter of 60-65 Å and an average length of 50 nm (C) Electron
micrograph of elongated L55P-TTR protofilaments (110 nm average
length) that form at 37 °C after 1-1.5 months of incubation. For
all micrographs, the scale bar ) 100 nm, magnification is 145000.
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that L55P-TTR is most sensitive to acidic dissociation,
followed by the V30M variant, followed by the WT protein,
as discerned from previous studies (16, 30, 31, 33). The effect
of concentration on the tetramer-monomer equilibrium at
neutral pH is not easily detected for WT-TTR or for the FAP
variant V30M, whereas the effect is significant and easily
detected for L55P-TTR. Transthyretin is a negative acute
phase reactant protein, meaning that its concentration is
reduced during inflammation and/or malnourishment (68).
A drop in L55P-TTR concentration in response to these
stimuli could actually increase the concentration of the
amyloidogenic intermediate at neutral pH and could play a
role in familial amyloid polyneuropathy under inflammatory
stress, especially when the L55P variant is involved.
Wild-type and V30M TTR will only form fibrils efficiently
under acidic conditions, suggesting late endosome or lyso-
some involvement in TTR amyloid diseases (29). It appears
that the activation barrier for WT and V30M-TTR tetramer
dissociation is simply not surmountable under physiological
conditions (16, 31). On the other hand, the L55P FAP-
associated variant will dissociate and form the monomeric
amyloidogenic intermediate that assembles into protofila-
ments under physiological conditions, suggesting that L55P-
TTR fibrils could form in the extracellular space as well as
in intracellular (e.g., lysosomal) locations (pH-mediated) (16).
Importantly, the extent of L55P-TTR amyloid fibril formation
is dramatically enhanced under acidic conditions, Figure 2,
leading one to speculate that an acidic environment may be
the physiologically relevant means of amyloid formation in
vivo, especially when the half-life of transthyretin is con-
sidered (maximally 72 h). Only traces of monomer are
produced over this time frame as can be seen in Figures 3
and 6 at pH 7.0. However, the half-life of L55P-TTR in
plasma becomes irrelevant if the protofilaments resulting
from its assembly can avoid turnover. Cell biological studies
currently underway in the laboratory will address these
possible scenarios directly.
It is not yet clear how closely the protofilaments formed
at pH 7.0 are in structure to the filaments composing the
amyloid fibrils; however, they do bind Congo red and
thioflavin T, albeit more weakly. Further studies are neces-
sary to compare their structures and to decide which of these
structures are relevant to pathology.
A common mechanism has emerged for the conversion
of wild-type, V30M and L55P transthyretin into amyloid
fibrils; however, the kinetics and thermodynamics of this
process differ significantly for L55P-TTR relative to WT
and V30M-TTR. In all cases, the functional tetrameric form
of transthyretin dissociates under acidic conditions into a
monomeric amyloidogenic intermediate that self-associates
into protofilaments, filaments, and fibrils, Figure 11. The
activation barrier for L55P-TTR tetramer dissociation is
surmountable under physiological conditions, which is not
the case for WT- or V30M-TTR. That this is the case is
easily discernible from time dependent TEM studies (Figure
10) and the observation that WT- and V30M-TTR exhibit
hysteresis when subjected to Gdn-HCl-induced unfolding
and dilution induced refolding, unlike L55P where the folded
and unfolded states are in equilibrium in the transition region
(66). The L55P-TTR tetramer is less stable than the WT-
TTR tetramer under physiological and acidic conditions as
well as toward denaturants, such as Gdn-HCl. The L55P-
TTR tetramer is predisposed to form the amyloidogenic
intermediate owing to favorable kinetics and thermodynam-
ics. Since tetramer dissociation appears to be the first
committed step in amyloid fibril formation, the small
molecule approach developed earlier by this laboratory to
prevent amyloid fibril formation should be quite effective
for reducing or eliminating amyloid fibril formation in
familial amyloid polyneuropathy associated with L55P-TTR
(23-26). One advantage to the slow in vitro conversion of
protofilaments into fibrils exhibited by L55P-TTR at neutral
pH (Figure 11) is that it may be possible to eliminate the
fibrils as the key suspect in the neurodegeneration using this
variant. If this holds true in cell culture experiments, then it
may be possible to narrow in on the culprit of neurodegen-
eration, i.e. to shed light on the key structural entity or entities
in neurodegeneration.
CONCLUSION
The L55P FAP-associated TTR variant tetramer-mono-
mer equilibrium exhibits greater sensitivity to acidification
and protein concentration (above pH 5.5 especially) than
either the WT or V30M FAP variant. The ability of L55P-
TTR to dissociate to an amyloidogenic monomer under
conditions where WT and V30M TTR exhibit a stable
tetrameric structure seems to explain the extreme pathogenic-
ity of the L55P variant. Subtle tertiary structural changes in
the L55P monomer appear to enable self-assembly of this
intermediate into protofilaments. Importantly, these results
suggest a common mechanism for TTR amyloid fibril
formation and, therefore, a common therapeutic strategy can
be envisioned for preventing fibril formation in the diseases
SSA and FAP, even though the kinetic barriers for L55P
and WT-TTR differ dramatically (1, 16, 66).
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FIGURE 11: Summary of our current understanding of the amy-
loidogenic properties of L55P-TTR.
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